Carrie I. Ho

Hematology

400 Parnassus Ave Fl 3
San Francisco, CA 94143

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

CGE26-139: Genomic Signatures of CNS and Systemic Relapse in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Profiled With Next Generation Sequencing (NGS).

CGE26-139: Genomic Signatures of CNS and Systemic Relapse in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Profiled With Next Generation Sequencing (NGS).

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: April 16, 2026

CGE26-139: Genomic Signatures of CNS and Systemic Relapse in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Profiled With Next Generation Sequencing (NGS).

CGE26-139: Genomic Signatures of CNS and Systemic Relapse in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Profiled With Next Generation Sequencing (NGS).

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: April 01, 2026

Barriers to Investigator-Initiated Clinical Trial Enrollment in Frontline Large B-Cell Lymphoma.

Barriers to Investigator-Initiated Clinical Trial Enrollment in Frontline Large B-Cell Lymphoma.

Journal: Clinical lymphoma, myeloma & leukemia

Published: September 14, 2025

Prognostic Implication of Karyotypic Evaluation in Patients With Richter Transformation in the Modern Era.

Prognostic Implication of Karyotypic Evaluation in Patients With Richter Transformation in the Modern Era.

Journal: American journal of hematology

Published: May 07, 2025

Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab.

Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab.

Journal: Blood

Published: March 06, 2025

Outcomes of patients with Richter transformation who received no prior chemoimmunotherapy for their CLL.

Outcomes of patients with Richter transformation who received no prior chemoimmunotherapy for their CLL.

Journal: Blood cancer journal

Published: January 10, 2025

Real-World Treatment Patterns and Clinical Outcomes in Patients With Multiple Myeloma Previously Treated With Lenalidomide and an Anti-CD38 Monoclonal Antibody.

Real-World Treatment Patterns and Clinical Outcomes in Patients With Multiple Myeloma Previously Treated With Lenalidomide and an Anti-CD38 Monoclonal Antibody.

Journal: Clinical lymphoma, myeloma & leukemia

Published: August 29, 2024

A phase 2 study of frontline pembrolizumab in follicular lymphoma.

A phase 2 study of frontline pembrolizumab in follicular lymphoma.

Journal: EJHaem

Published: July 18, 2024

Loncastuximab in high-risk and heavily pretreated relapsed/refractory diffuse large B-cell lymphoma: a realworld analysis from 21 US centers.

Loncastuximab in high-risk and heavily pretreated relapsed/refractory diffuse large B-cell lymphoma: a realworld analysis from 21 US centers.

Journal: Haematologica

Published: June 06, 2024

Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: An International, Multicenter, Retrospective Study.

Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: An International, Multicenter, Retrospective Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: March 29, 2024

More than a lonca-shot: beating the odds in relapsed/ refractory diffuse large B-cell lymphoma.

More than a lonca-shot: beating the odds in relapsed/ refractory diffuse large B-cell lymphoma.

Journal: Haematologica

Published: September 11, 2023

Pembrolizumab With R-CHOP in Previously Untreated DLBCL: Sustained, High Efficacy, and Safety With Long-Term Follow-Up.

Pembrolizumab With R-CHOP in Previously Untreated DLBCL: Sustained, High Efficacy, and Safety With Long-Term Follow-Up.

Journal: Clinical lymphoma, myeloma & leukemia

Published: August 29, 2023

Showing 1-12 of 15

Last Updated: 09/26/2026